Inactive Instrument

La Jolla Pharmaceutical Company Stock price

Equities

LJPC

US5034596040

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 61 20-05-31
Chief Tech/Sci/R&D Officer - 21-09-11
Chief Operating Officer 60 18-12-31
Members of the board TitleAgeSince
Director/Board Member 55 22-08-21
Director/Board Member 40 22-08-21
More insiders
La Jolla Pharmaceutical Company is primarily engaged in the commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
More about the company
  1. Stock
  2. Equities
  3. Stock La Jolla Pharmaceutical Company - Nasdaq